Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS - PubMed (original) (raw)
Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS
J-H Chen et al. NMR Biomed. 2011 Apr.
Abstract
This study investigated the association between the total choline (tCho) concentration and the clinical characteristics and biomarker status of breast cancer. Sixty-two patients with breast cancer, 1.5 cm or larger in size on MR images, were studied. The tCho concentration was correlated with the MRI features, contrast enhancement kinetics, clinical variables and biomarkers. Pairwise two-tailed Spearman's nonparametric test was used for statistical analysis. The tCho concentration was higher in high-grade than moderate-/low-grade tumors (p = 0.04) and in tumors with higher K(trans) and k(ep) (p < 0.001 for both). The association of tCho concentration with age (p = 0.05) and triple negative biomarker (p = 0.09) approached significance. tCho was not detected in 17 patients, including 15 with invasive ductal cancer and two with infiltrating lobular cancer. Fifteen of the 17 patients had moderate- to low-grade cancers, and 11 had human epidermal growth factor-2-negative cancer, suggesting that these two factors might lead to false-negative choline. Higher tCho concentration in high-grade tumors and tumors with higher K(trans) and k(ep) indicates that choline is associated with cell proliferation and tumor angiogenesis. The higher choline level in younger women may be caused by their more aggressive tumor type. The results presented here may aid in the better interpretation of (1)H MRS for the diagnosis of breast lesions.
Copyright © 2010 John Wiley & Sons, Ltd.
Figures
Figure 1
A 62 y/o woman with a 3.4×3.3cm high grade invasive ductal cancer in her right breast. The 1H MRS showed a high choline peak (6.97 mmol/kg) at the 3.2ppm location. The biomarkers information was not available in this patient.
Figure 2
A 66 y/o woman with a 2.7×2.6cm moderate grade, Her-2 negative, ER-positive invasive ductal cancer in the left breast. The 1H MRS showed a low choline peak (1.79 mmol/kg) at the 3.2ppm location.
Figure 3
A 35 y/o woman with a 3.5×2.7cm high grade, triple negative invasive ductal cancer in the right breast. The 1H MRS showed a choline peak (4.33 mmol/kg) at the 3.2ppm location.
Figure 4
A 32 y/o woman status post breast augmentation with a 3.5×2.0 cm ill-defined margin heterogeneously enhanced invasive ductal cancer in her left breast. The tumor was high grade, Her-2 negative, and hormonal positive. The choline peak was not detectable in the 1H MRS spectra.
Figure 5
A 50 y/o woman with a 4.1×2.1cm regional enhancement of infiltrative lobular cancer in her left breast. The tumor was low grade, Her-2 positive, and hormonal negative. The choline peak was not detectable in the 1H MRS spectra.
Figure 6
A 58 y/o woman with a 2.8×2.2cm ill-defined margin heterogeneously enhanced invasive ductal cancer in her left breast. The tumor was moderate grade, Her-2 positive, and hormonal negative. The choline peak was not detectable in the 1H MRS spectra.
References
- Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodríguez-González A, Olmeda D, Megías D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004;64:6732–6739. -PubMed
- Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006;19(1):30–40. -PubMed
- Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjøsne HE, Haraldseth O. Characterization of neoplastic and normal human breast tissues with in vivo (1) H MR spectroscopy. J Magn Reson Imaging. 1999;10:159–164. -PubMed
- Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast enhanced in vivo proton MR spectroscopy initial results. Radiology. 2001;220:40–46. -PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA90437/CA/NCI NIH HHS/United States
- R01 CA090437/CA/NCI NIH HHS/United States
- P30 CA062203/CA/NCI NIH HHS/United States
- R03 CA136071/CA/NCI NIH HHS/United States
- R01 CA127927/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical